Bacterial Outer Membrane Vesicles and Vaccine Applications

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2014 Apr 10

PMID 24715891

Citations 112

Authors

Reinaldo Acevedo

Sonsire Fernandez

Caridad Zayas

Armando Acosta

Maria Elena Sarmiento

Valerie A Ferro

Einar Rosenqvist

Concepcion Campa

Daniel Cardoso

Luis Garcia

Jose Luis Perez

Affiliations

Soon will be listed here.

Abstract

Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of meningococcal antigens or unrelated antigens incorporated into the vesicle structure. This paper reviews different applications in OMV Research and Development (R&D) and provides examples of OMV developed and evaluated at the Finlay Institute in Cuba. A Good Manufacturing Practice (GMP) process was developed at the Finlay Institute to produce OMV from N. meningitidis serogroup B (dOMVB) using detergent extraction. Subsequently, OMV from N. meningitidis, serogroup A (dOMVA), serogroup W (dOMVW), and serogroup X (dOMVX) were obtained using this process. More recently, the extraction process has also been applied effectively for obtaining OMV on a research scale from Vibrio cholerae (dOMVC), Bordetella pertussis (dOMVBP), Mycobacterium smegmatis (dOMVSM), and BCG (dOMVBCG). The immunogenicity of the OMV has been evaluated for specific antibody induction, and together with functional bactericidal and challenge assays in mice has shown their protective potential. dOMVB has been evaluated with non-neisserial antigens, including with a herpes virus type 2 glycoprotein, ovalbumin, and allergens. In conclusion, OMV are proving to be more versatile than first conceived and remain an important technology for development of vaccine candidates.

Citing Articles

Review on bacterial outer membrane vesicles: structure, vesicle formation, separation and biotechnological applications.

Zhao X, Wei Y, Bu Y, Ren X, Dong Z Microb Cell Fact. 2025; 24(1):27.

PMID: 39833809 PMC: 11749425. DOI: 10.1186/s12934-025-02653-9.

Immunomodulatory properties of extracellular vesicles containing the Spike protein of SARS-CoV-2.

Medina A, Acevedo Ospina H, Descoteaux A Front Parasitol. 2025; 3():1306478.

PMID: 39817166 PMC: 11731608. DOI: 10.3389/fpara.2024.1306478.

Effects of Yersinia pseudotuberculosis outer membrane vesicles on Pseudomonas aeruginosa antigens immune response.

Duan Z, Song J, Zhang M, Zhang Z, Li N, Fu Y PLoS One. 2024; 19(12):e0310652.

PMID: 39705292 PMC: 11661608. DOI: 10.1371/journal.pone.0310652.

Cargo exchange between human and bacterial extracellular vesicles in gestational tissues: a new paradigm in communication and immune development.

Amabebe E, Kumar A, Tatiparthy M, Kumar Kammala A, Taylor B, Menon R Extracell Vesicles Circ Nucl Acids. 2024; 5(2):297-328.

PMID: 39698538 PMC: 11648491. DOI: 10.20517/evcna.2024.21.

Vaccination with outer membrane vesicles from Neisseria Meningitidis and SBa15, SBa16 mesoporous silica associated with SARS-CoV-2 induces protective humoral and cellular response against COVID-19 in mice.

Bernardes B, Moura A, Guarnieri J, Silva C, Costa H, Martins da Silva I Braz J Infect Dis. 2024; 28(6):104479.

PMID: 39547005 PMC: 11609543. DOI: 10.1016/j.bjid.2024.104479.

References

Rohani P, Drake J . The decline and resurgence of pertussis in the US. Epidemics. 2011; 3(3-4):183-8. DOI: 10.1016/j.epidem.2011.10.001. View

Lowell G, Ballou W, SMITH L, Wirtz R, Zollinger W, Hockmeyer W . Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science. 1988; 240(4853):800-2. DOI: 10.1126/science.2452484. View

Witt M, Arias L, Katz P, Truong E, Witt D . Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis. 2013; 56(9):1248-54. DOI: 10.1093/cid/cit046. View

Sierra G, Campa H, Varcacel N, Garcia I, Izquierdo P, Sotolongo P . Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991; 14(2):195-207; discussion 208-10. View

Agger E, Rosenkrands I, Hansen J, Brahimi K, Vandahl B, Aagaard C . Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One. 2008; 3(9):e3116. PMC: 2525815. DOI: 10.1371/journal.pone.0003116. View

Rosenqvist E, Hoiby E, Wedege E, Bryn K, Kolberg J, Klem A . Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun. 1995; 63(12):4642-52. PMC: 173667. DOI: 10.1128/iai.63.12.4642-4652.1995. View

Norheim G, Tunheim G, Naess L, Kristiansen P, Caugant D, Rosenqvist E . An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt. Scand J Immunol. 2012; 76(2):99-107. DOI: 10.1111/j.1365-3083.2012.02709.x. View

Tunheim G, Arnemo M, Naess L, Fjeldheim A, Nome L, Bolstad K . Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines. Vaccine. 2013; 31(51):6097-106. DOI: 10.1016/j.vaccine.2013.09.044. View

Brennan P . Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb). 2003; 83(1-3):91-7. DOI: 10.1016/s1472-9792(02)00089-6. View

10.

Lastre M, Perez O, Labrada A, Bidot I, Perez J, Bracho G . Bacterial derived proteoliposome for allergy vaccines. Vaccine. 2006; 24 Suppl 2:S2-34-5. DOI: 10.1016/j.vaccine.2005.01.110. View

11.

Rodriguez L, Tirado Y, Reyes F, Puig A, Kadir R, Borrero R . Proteoliposomes from Mycobacterium smegmatis induce immune cross-reactivity against Mycobacterium tuberculosis antigens in mice. Vaccine. 2011; 29(37):6236-41. DOI: 10.1016/j.vaccine.2011.06.077. View

12.

Perez O, Lastre M, Cabrera O, Del Campo J, Bracho G, Cuello M . New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand J Immunol. 2007; 66(2-3):271-7. DOI: 10.1111/j.1365-3083.2007.01981.x. View

13.

Schild S, Nelson E, Camilli A . Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun. 2008; 76(10):4554-63. PMC: 2546833. DOI: 10.1128/IAI.00532-08. View

14.

Perez J, Acevedo R, Callico A, Fernandez Y, Cedre B, Ano G . A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice. Vaccine. 2008; 27(2):205-12. DOI: 10.1016/j.vaccine.2008.10.052. View

15.

Mesa C, Leon J, Fernandez L . Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine. 2005; 24(14):2692-9. DOI: 10.1016/j.vaccine.2005.08.111. View

16.

Caugant D, Kristiansen P, Wang X, Mayer L, Taha M, Ouedraogo R . Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One. 2012; 7(9):e46019. PMC: 3459830. DOI: 10.1371/journal.pone.0046019. View

17.

Coulombe F, Divangahi M, Veyrier F, de Leseleuc L, Gleason J, Yang Y . Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med. 2009; 206(8):1709-16. PMC: 2722178. DOI: 10.1084/jem.20081779. View

18.

Xie O, Pollard A, Mueller J, Norheim G . Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine. 2013; 31(27):2852-61. DOI: 10.1016/j.vaccine.2013.04.036. View

19.

Williams J, Skipp P, Humphries H, Christodoulides M, OConnor C, Heckels J . Proteomic analysis of outer membranes and vesicles from wild-type serogroup B Neisseria meningitidis and a lipopolysaccharide-deficient mutant. Infect Immun. 2006; 75(3):1364-72. PMC: 1828559. DOI: 10.1128/IAI.01424-06. View

20.

Rodriguez T, Perez O, Ugrinovic S, Bracho G, Mastroeni P . Bacterial derived proteoliposome as ideal delivery system and cellular adjuvant. Vaccine. 2006; 24 Suppl 2:S2-24-5. DOI: 10.1016/j.vaccine.2005.01.106. View